We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Low-Dose Colchicine Reduces Myocardial Infarction and Stroke Risk in Cardiovascular Disease Patients

MedXY Editorial Team•Dec 16, 2025•Cardiology
cardiovascular diseasecolchicinemyocardial infarctionSecondary Prevention

Highlights

  • High-certainty evidence supports low-dose colchicine in reducing myocardial infarction and stroke risk in patients with established cardiovascular disease.
  • No increase in serious adverse events was observed, but gastrointestinal side effects were more common.
  • No significant reduction in all-cause or cardiovascular mortality, or coronary revascularisation rates.
  • Further research is needed to clarify benefits in specific subgroups and long-term use in stable coronary artery disease.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Inpatient Rehabilitation and Major Adverse Cardiovascular Events After Ischemic Stroke: Clinical Implications and Evidence SynthesisPostacute discharge to inpatient rehabilitation facilities (IRF) after acute ischemic stroke (AIS) is associated with a reduced 1-year risk of major adverse cardiovascular events (MACE) compared to discharge to home or skilled nursing facilSep 19, 2026Targeting the CCND1-PDK4 Axis to Promote Reparative Macrophage Phenotype and Mitigate Post-Myocardial Infarction Cardiac RemodelingThis article discusses the role of cyclin D1 (CCND1) in promoting reparative macrophage transition post-myocardial infarction, highlighting its therapeutic potential in reducing adverse cardiac remodeling through metabolic reprogramming.Sep 19, 2026Evaluating Targeted Vitamin D Supplementation Post-Myocardial Infarction: Insights from the TARGET-D TrialThe TARGET-D trial investigated whether vitamin D supplementation, titrated to achieve serum levels >40-80 ng/mL, reduces major adverse cardiovascular events after myocardial infarction but found no significant benefit in the primary comSep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Comparing 0/1-Hour vs 0/3-Hour High-Sensitivity Troponin Pathways for Suspected Acute Coronary Syndrome in Real-World Practice
This randomized trial evaluates the safety and efficiency of the ESC 0/1-hour versus 0/3-hour high-sensitivity troponin pathways in suspected acute coronary syndrome, showing noninferior safety but no significant improvement in rapid discha
Sep 17, 2026
Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026
Unveiling the Cardiovascular Toll of Long-Term Wildfire Smoke PM2.5 Exposure in Older AmericansLong-term cumulative exposure to wildfire smoke PM2.5 significantly increases cardiovascular hospitalizations among U.S. older adults, with notable risks in ischemic heart disease and arrhythmias, highlighting the need for targeted public hSep 15, 2026